146 related articles for article (PubMed ID: 32875516)
21. Learning from cerebrospinal fluid drug-resistant HIV escape-associated encephalitis: a case report.
Kang J; Wang Z; Zhou Y; Wang W; Wen Y
Virol J; 2023 Dec; 20(1):292. PubMed ID: 38072961
[TBL] [Abstract][Full Text] [Related]
22. Persistent intrathecal immune activation in HIV-1-infected individuals on antiretroviral therapy.
Yilmaz A; Price RW; Spudich S; Fuchs D; Hagberg L; Gisslén M
J Acquir Immune Defic Syndr; 2008 Feb; 47(2):168-73. PubMed ID: 17971711
[TBL] [Abstract][Full Text] [Related]
23. Dynamic of CSF and serum biomarkers in HIV-1 subtype C encephalitis with CNS genetic compartmentalization-case study.
de Almeida SM; Rotta I; Ribeiro CE; Oliveira MF; Chaillon A; de Pereira AP; Cunha AP; Zonta M; Bents JF; Raboni SM; Smith D; Letendre S; Ellis RJ
J Neurovirol; 2017 Jun; 23(3):460-473. PubMed ID: 28247269
[TBL] [Abstract][Full Text] [Related]
24. Evaluation of cerebrospinal fluid virological escape in patients on long-term protease inhibitor monotherapy.
Arenas-Pinto A; Stöhr W; Clarke A; Williams I; Beeching NJ; Minton J; Lee V; Paton NI;
Antivir Ther; 2017; 22(6):535-538. PubMed ID: 28234235
[TBL] [Abstract][Full Text] [Related]
25. Cerebrospinal fluid viral escape in aviremic HIV-infected patients receiving antiretroviral therapy: prevalence, risk factors and neurocognitive effects.
Pérez-Valero I; Ellis R; Heaton R; Deutsch R; Franklin D; Clifford DB; Collier A; Gelman B; Marra C; McCutchan JA; Navis A; Sacktor N; Simpson D; Grant I; Letendre S
AIDS; 2019 Mar; 33(3):475-481. PubMed ID: 30702516
[TBL] [Abstract][Full Text] [Related]
26. Cerebrospinal fluid drug concentrations and viral suppression in HIV-1-infected patients receiving ritonavir-boosted atazanavir plus lamivudine dual antiretroviral therapy (Spanish HIV/AIDS Research Network, PreEC/RIS 39).
Imaz A; Niubó J; Amara A; Khoo S; Ferrer E; Tiraboschi JM; Acerete L; Garcia B; Vila A; Podzamczer D
J Neurovirol; 2018 Aug; 24(4):391-397. PubMed ID: 29542028
[TBL] [Abstract][Full Text] [Related]
27. Low levels of HIV-1 RNA detected in the cerebrospinal fluid after up to 10 years of suppressive therapy are associated with local immune activation.
Dahl V; Peterson J; Fuchs D; Gisslen M; Palmer S; Price RW
AIDS; 2014 Sep; 28(15):2251-8. PubMed ID: 25022595
[TBL] [Abstract][Full Text] [Related]
28. Effect of genotypic resistance on the virological response to highly active antiretroviral therapy in cerebrospinal fluid.
Cinque P; Presi S; Bestetti A; Pierotti C; Racca S; Boeri E; Morelli P; Carrera P; Ferrari M; Lazzarin A
AIDS Res Hum Retroviruses; 2001 Mar; 17(5):377-83. PubMed ID: 11282006
[TBL] [Abstract][Full Text] [Related]
29. Cerebrospinal fluid viral replication and burden of resistance in three HIV-1-infected people taking Ibalizumab with multiple drug class-wide resistance.
Muccini C; Spagnuolo V; Canetti D; Bigoloni A; Cernuschi M; Franzin M; Sampaolo M; Castagna A
AIDS; 2020 Nov; 34(14):2152-2155. PubMed ID: 33105172
[No Abstract] [Full Text] [Related]
30. Discordant CSF/plasma HIV-1 RNA in patients with unexplained low-level viraemia.
Nightingale S; Geretti AM; Beloukas A; Fisher M; Winston A; Else L; Nelson M; Taylor S; Ustianowski A; Ainsworth J; Gilson R; Haddow L; Ong E; Watson V; Leen C; Minton J; Post F; Pirmohamed M; Solomon T; Khoo S
J Neurovirol; 2016 Dec; 22(6):852-860. PubMed ID: 27194435
[TBL] [Abstract][Full Text] [Related]
31. Diffuse White Matter Signal Abnormalities on Magnetic Resonance Imaging Are Associated With Human Immunodeficiency Virus Type 1 Viral Escape in the Central Nervous System Among Patients With Neurological Symptoms.
Kugathasan R; Collier DA; Haddow LJ; El Bouzidi K; Edwards SG; Cartledge JD; Miller RF; Gupta RK
Clin Infect Dis; 2017 Apr; 64(8):1059-1065. PubMed ID: 28329096
[TBL] [Abstract][Full Text] [Related]
32. Prevalence and Correlates of Persistent HIV-1 RNA in Cerebrospinal Fluid During Antiretroviral Therapy.
Anderson AM; Muñoz-Moreno JA; McClernon DR; Ellis RJ; Cookson D; Clifford DB; Collier AC; Gelman BB; Marra CM; McArthur JC; McCutchan JA; Morgello S; Sacktor N; Simpson DM; Franklin DR; Heaton RK; Grant I; Letendre SL;
J Infect Dis; 2017 Jan; 215(1):105-113. PubMed ID: 27789723
[TBL] [Abstract][Full Text] [Related]
33. Cerebrospinal Fluid HIV-1 Escape in Patients With Neurocognitive Symptoms: Pooled Data From a Neuro-HIV Platform and the NAMACO Study.
Filippidis P; Damas J; Viala B; Assal F; Nawej Tshikung O; Tarr P; Derfuss T; Oberholzer M; Jelcic I; Hundsberger T; Sacco L; Cavassini M; Du Pasquier R; Darling KEA;
J Acquir Immune Defic Syndr; 2023 Jul; 93(3):219-228. PubMed ID: 36927958
[TBL] [Abstract][Full Text] [Related]
34. Cerebrospinal fluid HIV-1 infection usually responds well to antiretroviral treatment.
Mellgren A; Antinori A; Cinque P; Price RW; Eggers C; Hagberg L; Gisslén M
Antivir Ther; 2005; 10(6):701-7. PubMed ID: 16218168
[TBL] [Abstract][Full Text] [Related]
35. HIV Type 1 replication in cerebrospinal fluid of patients with AIDS-related non-Hodgkin's lymphoma receiving chemotherapy and antiretroviral therapy.
Giancola ML; Uccella I; Alba L; Lorenzini P; Soldani F; Capobianchi M; Ruco L; Perno CF; Antinori A
AIDS Res Hum Retroviruses; 2003 Dec; 19(12):1091-5. PubMed ID: 14709245
[TBL] [Abstract][Full Text] [Related]
36. Cerebrospinal fluid HIV escape associated with progressive neurologic dysfunction in patients on antiretroviral therapy with well controlled plasma viral load.
Peluso MJ; Ferretti F; Peterson J; Lee E; Fuchs D; Boschini A; Gisslén M; Angoff N; Price RW; Cinque P; Spudich S
AIDS; 2012 Sep; 26(14):1765-74. PubMed ID: 22614889
[TBL] [Abstract][Full Text] [Related]
37. Study of the impact of HIV genotypic drug resistance testing on therapy efficacy.
Van Vaerenbergh K
Verh K Acad Geneeskd Belg; 2001; 63(5):447-73. PubMed ID: 11813503
[TBL] [Abstract][Full Text] [Related]
38. HIV-1 replication in central nervous system increases over time on only protease inhibitor therapy.
Donath M; Wolf T; Stürmer M; Herrmann E; Bickel M; Khaykin P; Göpel S; Gute P; Haberl A; de Leuw P; Schüttfort G; Berger A; Stephan C;
Med Microbiol Immunol; 2016 Dec; 205(6):575-583. PubMed ID: 27469377
[TBL] [Abstract][Full Text] [Related]
39. Cerebrospinal fluid viral load in HIV-1-infected patients without antiretroviral treatment: a longitudinal study.
Gisslén M; Hagberg L; Fuchs D; Norkrans G; Svennerholm B
J Acquir Immune Defic Syndr Hum Retrovirol; 1998 Apr; 17(4):291-5. PubMed ID: 9525428
[TBL] [Abstract][Full Text] [Related]
40. CSF replication reduced with Sustiva.
AIDS Patient Care STDS; 1998 Oct; 12(10):802. PubMed ID: 11362028
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
